NCT02726399

Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer

Phase II Study of Ramucirumab With Trastuzumab, Fluoropyrimidine, and Platinum in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare any good and bad effects of using ramucirumab along with the usual trastuzumab and chemotherapy to using the usual chemotherapy and trastuzumab alone.

Conditions

• Gastric Cancer
• Gastroesophageal Junction Cancer

Interventions

Type	Name	Description
DRUG	Ramucirumab	Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days
DRUG	Trastuzumab	Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
DRUG	Capecitabine	Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period
DRUG	Cisplatin	Cisplatin 80mg/m2 administered as an IV infusion every 21 days

Timeline

• Start date: 2016-03-18
• Primary completion: 2019-02-26
• Completion: 2019-02-26
• First posted: 2016-04-01
• Last updated: 2020-01-21
• Results posted: 2020-01-07

Locations

6 sites across 1 country: United States